UA116776C2 - Лікарська форма для продовженого вивільнення діючих речовин - Google Patents

Лікарська форма для продовженого вивільнення діючих речовин

Info

Publication number
UA116776C2
UA116776C2 UAA201500503A UAA201500503A UA116776C2 UA 116776 C2 UA116776 C2 UA 116776C2 UA A201500503 A UAA201500503 A UA A201500503A UA A201500503 A UAA201500503 A UA A201500503A UA 116776 C2 UA116776 C2 UA 116776C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical form
active substances
extended release
active substance
release
Prior art date
Application number
UAA201500503A
Other languages
English (en)
Inventor
Ґернот Франкас
Карл-Хайнц Прзикленк
Original Assignee
Хенніґ Арцнайміттель Ґмбх Унд Ко. Кґ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хенніґ Арцнайміттель Ґмбх Унд Ко. Кґ filed Critical Хенніґ Арцнайміттель Ґмбх Унд Ко. Кґ
Publication of UA116776C2 publication Critical patent/UA116776C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описується лікарська форма, яка дозволяє рівномірно вивільняти діючу речовину протягом більш тривалого періоду часу. Лікарська форма містить емульгатор зі структурним мотивом поліалкіленоксиду. Лікарська форма придатна для того, щоб вивільняти поряд з першою діючою речовиною другу діючу речовину. При цьому рівномірне вивільнення може бути досягнуте й тоді, коли обидві діючі речовини мають зовсім різні властивості щодо їх розчинності. Описуються також способи виготовлення лікарської форми та її застосування.
UAA201500503A 2012-06-25 2013-06-24 Лікарська форма для продовженого вивільнення діючих речовин UA116776C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012105512.2A DE102012105512A1 (de) 2012-06-25 2012-06-25 Arzneiform zur verlängerten Freisetzung von Wirkstoffen
PCT/EP2013/063163 WO2014001268A1 (de) 2012-06-25 2013-06-24 Arzneiform zur verlängerten freisetzung von wirkstoffen

Publications (1)

Publication Number Publication Date
UA116776C2 true UA116776C2 (uk) 2018-05-10

Family

ID=48670585

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201500503A UA116776C2 (uk) 2012-06-25 2013-06-24 Лікарська форма для продовженого вивільнення діючих речовин

Country Status (22)

Country Link
EP (1) EP2863891B1 (uk)
KR (1) KR102160837B1 (uk)
AU (1) AU2013283474B2 (uk)
BR (1) BR112014032583B1 (uk)
CA (1) CA2876294C (uk)
CO (1) CO7240370A2 (uk)
DE (1) DE102012105512A1 (uk)
EA (2) EA028064B1 (uk)
ES (1) ES2817248T3 (uk)
HR (1) HRP20201534T1 (uk)
HU (1) HUE050945T2 (uk)
IL (1) IL236465B (uk)
IN (1) IN2014MN02511A (uk)
LT (1) LT2863891T (uk)
MX (1) MX371143B (uk)
PH (1) PH12014502834A1 (uk)
PL (1) PL2863891T3 (uk)
PT (1) PT2863891T (uk)
RS (1) RS60872B1 (uk)
SI (1) SI2863891T1 (uk)
UA (1) UA116776C2 (uk)
WO (1) WO2014001268A1 (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
HUE043399T2 (hu) * 2014-06-26 2019-08-28 Hennig Arzneimittel Gmbh&Co Kg Gyógyszer, különbözõ okokból eredõ szédülés kezelésére
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR101625344B1 (ko) * 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
JP2001520984A (ja) * 1997-10-27 2001-11-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 水難溶性薬剤の固態溶剤及び固体分散体
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
EP1942888A2 (en) 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CN101049309A (zh) * 2006-04-03 2007-10-10 陈茜 桂利嗪滴丸及其制备方法
WO2009040818A1 (en) * 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
JP5646340B2 (ja) * 2007-12-12 2014-12-24 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリマー性対イオンと活性成分との塩
PE20120858A1 (es) * 2009-06-11 2012-08-01 Photocure Asa Composiciones solidas que comprenden acido 5-aminolevulinico
WO2011024029A1 (en) * 2009-08-24 2011-03-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Fast disintegrating dosage forms of cinnarizine and dimenhydrinate combination
DE102011051304A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Wirkstoffmatrix
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
DE102011053068A1 (de) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Darreichungsform mit stabilisierten Wirkstoffpartikeln

Also Published As

Publication number Publication date
BR112014032583A2 (pt) 2017-06-27
WO2014001268A1 (de) 2014-01-03
EP2863891B1 (de) 2020-08-26
PT2863891T (pt) 2020-09-25
IL236465A0 (en) 2015-02-26
HRP20201534T1 (hr) 2021-02-19
PH12014502834B1 (en) 2015-02-02
LT2863891T (lt) 2020-12-10
HUE050945T2 (hu) 2021-01-28
DE102012105512A1 (de) 2014-04-24
BR112014032583A8 (pt) 2021-06-22
EP2863891A1 (de) 2015-04-29
AU2013283474B2 (en) 2017-12-14
AU2013283474A1 (en) 2015-01-29
PH12014502834A1 (en) 2015-02-02
CA2876294A1 (en) 2014-01-03
PL2863891T3 (pl) 2021-01-25
EA201500043A1 (ru) 2015-09-30
IL236465B (en) 2020-06-30
CO7240370A2 (es) 2015-04-17
RS60872B1 (sr) 2020-11-30
ES2817248T3 (es) 2021-04-06
KR102160837B1 (ko) 2020-09-29
MX371143B (es) 2020-01-20
EA035815B1 (ru) 2020-08-14
SI2863891T1 (sl) 2020-11-30
MX2014015642A (es) 2015-08-05
EA201792143A1 (ru) 2018-05-31
CA2876294C (en) 2020-09-08
KR20150041612A (ko) 2015-04-16
BR112014032583B1 (pt) 2022-05-17
IN2014MN02511A (uk) 2015-07-17
EA028064B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12014502834B1 (en) Pharmaceutical form for extended release of active substances
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
EP2981612A4 (en) Compositions and methods for in vivo excision of hiv-1 proviral dna
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX2021001231A (es) Compuestos heterociclicos y sus usos.
EP3206706A4 (en) Stable injectable composition of pharmaceutically active agents and process for its preparation
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EP3235512A4 (en) Method using polyethylene glycol to prepare fibroin nano/microspheres, and application of method in controlled drug release
PH12015502535B1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
PT2736488E (pt) Composições farmacêuticas contendo rifaximina, processos para a sua preparação e sua utilização no tratamento de infeções vaginais
CL2015001020A1 (es) Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica
HK1197414A1 (zh) 雌甾- -四烯- -甲酰胺衍生物、其製備方法、包含其的藥物製劑及其用於製備藥物的用途
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MY191875A (en) Solid dosage form
MX2015012416A (es) Compuestos heterociclicos y sus usos.
TN2015000498A1 (en) Modified release formulation
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
EP2875814A4 (en) LIQUID COMPOSITION CONTAINING TAXANE ACTIVE INGREDIENT, MANUFACTURING METHOD THEREOF, AND LIQUID MEDICINAL PREPARATION
EP3311809A4 (en) USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION
MX361407B (es) Formulaciones de liberacion controlada de hidrocortisona.
CL2015000354A1 (es) Compuestos derivados de piridina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento o profilaxis de la diabetes, aterosclerosis, entre otras.